[Primary biliary cholangitis : an update].

Autor:	Vieira Barbosa J; Service de gastroentérologie et d'hépatologie, CHUV, 1011 Lausanne., Vionnet J; Service de gastroentérologie et d'hépatologie, CHUV, 1011 Lausanne.; Centre de transplantation d'organes, CHUV, 1011 Lausanne., Sciarra A; Institut de pathologie, CHUV, 1011 Lausanne., Sempoux C; Institut de pathologie, CHUV, 1011 Lausanne., Aubert V; Service d'immunologie et d'allergie, CHUV, Université de Lausanne, 1011 Lausanne., Moradpour D; Service de gastroentérologie et d'hépatologie, CHUV, 1011 Lausanne., Fraga Christinet M; Service de gastroentérologie et d'hépatologie, CHUV, 1011 Lausanne.
Jazyk:	francouzština
Zdroj:	Revue medicale suisse [Rev Med Suisse] 2018 Aug 29; Vol. 14 (616), pp. 1489-1494.
Abstrakt:	Primary biliary cholangitis (PBC) is an autoimmune liver disease which affects primarily women and is characterized by progressive destruction of small intrahepatic bile ducts. Most common symptoms are fatigue and pruritus. Diagnostic hallmarks are cholestasis and positive antimitochondrial antibodies. The first-line therapy is ursodeoxycholic acid (UDCA), with excellent results when started at an early stage. Nevertheless, 30‑40 % of patients do not achieve a complete biochemical response with UDCA. In these cases, the adjunction of obeticholic acid can be discussed. Fibrates appear to be a promising alternative. Liver transplantation yields excellent outcomes in advanced cases. Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêt en relation avec cet article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu